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Abstract
Pancreatic carcinomas with acinar differentiation 
are rare, accounting for 1%-2% of adult pancreatic 
tumors; they include pancreatic acinar cell carcinoma 
(PACC), pancreatoblastoma, and carcinomas of mixed 
differentiation. Patients with PACC have a progno-
sis better than pancreatic ductal adenocarcinomas 
but worse than pancreatic neuroendocrine tumors. 
Reports of overall survival range from 18 to 47 mo. A 
literature review on PACCs included comprehensive 
genomic profiling and whole exome sequencing on 
a series of more than 70 patients as well as other 
diagnostic studies including immunohistochemistry. 
Surgical resection of PACC is the preferred treatment 
for localized and resectable tumors. The efficacy 
of adjuvant treatment is unclear. Metastatic PACCs 
are generally not curable and treated with systemic 
chemotherapy. They are moderately responsive to 
chemotherapy with different regimens showing various 
degrees of response in case reports/series. Most of 
these regimens were developed to treat patients 
with pancreatic ductal adenocarcinomas or colorectal 
adenocarcinomas. Review of PACC’s molecular profiling 
showed a number of gene alterations such as: SMAD4, 
BRAF , BRCA2 , TP53 , RB1 , MEN1 , JAK-1 , BRCA-1 , 
BRCA-2 , and DNA mismatch repair abnormalities. 
PACCs had multiple somatic mutations with some 
targetable with available drugs. Therefore, molecular 
profiling of PACC should be an option for patients with 
refractory PACC.
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Core tip: This is a review article on pancreatic acinar 
cell carcinoma, which is a rare type of pancreatic 
cancer, with a series of molecularly profiled cases 
and an insight on how to potentially target specific 
mutations and genetic abnormalities with different 
systemic treatments including tyrosine kinase inhibitors, 
immunotherapy and cytotoxic chemotherapy agents. 
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INTRODUCTION
Pancreatic carcinomas with acinar differentiation are 
a very rare pancreatic neoplasm, comprising about 
1%-2% of all pancreatic tumors in adults[1-3]. These 
tumors also occur in children, accounting for 6% of 
all childhood tumors and more importantly, 15%, of 
all pediatric pancreatic tumors[1,2,4-6]. These pancreatic 
neoplasms include pancreatic acinar cell carcinoma 
(PACC), pancreatoblastoma, and carcinomas of mixed 
differentiation. They typically occur in late adulthood, 
with a mean age of 62 at diagnosis. They are more 
common in males with a male to female incidence 
ratio of 2:1[1,7]. Prognosis of patients with PACC is 
worse than that of pancreatic neuroendocrine tumors 
but better than that for patients with pancreatic ductal 
carcinomas, which has the worst prognosis of the three 
tumors[8-11]. Overall survival for PACC ranges from 
18-47 mo[8,9,11,12]. Although acinar cells are the most 
common cell types found in the pancreas, malignant 
transformation of these cells is very rare, as they 
involve only 1% of exocrine tumors of the pancreas[13]. 
In contrast, pancreatic ductal adenocarcinomas 
(PDACs), which arise from the epithelial lining of the 
pancreatic ducts, comprise the majority of pancreatic 
malignancies[1,9].
Morphologically, PACCs have different histological 
patterns, as they can appear to be normal pancreatic 
acini or they can be solid tumors with sheets of 
neoplastic cells that are poorly differentiated (Figure 
1). This wide variation in histology can make it difficult 
to distinguish PACCs from other types of pancreatic 
tumors. One method to distinguish PACCs from other 
pancreatic tumors is the use of immunohistochemistry 
to show the proteins that the tumor produces. In 
the case of PACC, they tend to make acinar-specific 
enzymes including proteases, lipases, and amylases. 
LITERATURE RESEARCH
The main search tool for identifying articles from 
MEDLINE was the PubMed system. The keywords 
used were “pancreatic cancer,” “acinar cell carcinoma,” 
“molecular biology,” and “sequencing.” Relevant articles 
that were quoted in publications from the original 
search were also used. Google Scholar was another 
search strategy and the search phrase was “pancreatic 
acinar cell carcinoma”.
CLINICAL PRESENTATION
Patients who present with PACCs usually have non-
specific symptoms. Their complaints consist of 
abdominal pain or discomfort, nausea, vomiting, 
weight loss, and diarrhea. Jaundice is less frequently 
seen at presentation. In about 50% of patients serum 
lipase is elevated, and up to 10% of these patients 
with lipase hypersecretion develop subcutaneous 
nodules erythematous and edematous subcutaneous 
nodules that occur in conjunction with eosinophilia, and 
polyarthralgia[6,12,14]. This condition, known as Schmid’s 
triad, is associated with a poor prognosis[15,16].
DIAGNOSIS
Diagnosing PACCs, like other pancreatic tumors, 
includes use of various imaging modalities including 
CT and/or MRI scans. PACCs are well-circumscribed 
tumors and can be large in diameter, although findings 
vary[7,17]. Imaging is followed by fine-needle aspiration 
guided by endoscopic ultrasound (EUS) or other 
techniques dependent upon tumor location to obtain 
a tissue diagnosis. Resectability is the most important 
prognostic factor for this disease, and the staging 
system used in PACCs is the same as the TNM staging 
used for PDACs. 
As mentioned above, PACCs have distinctive 
features, but there are some variations in appearance 
that make it difficult to distinguish PACCs from other 
pancreatic tumors. PACCs are usually highly cellular 
without a prominent stroma normally observed in 
PDACs[6]. The individual cells are uniform in size and 
shape with large nucleoli located in the center of the 
nucleus[6]. Other variants of PACC include acinar cell 
cystadenoma, which are grossly cystic neoplasms lined 
with simple cuboidal or columnar acinar cells. When a 
PACC has 25% to 30% of neoplastic endocrine cells, it 
is called a mixed acinar-endocrine carcinoma. In mixed 
acinar-endocrine carcinoma, there is evidence of 
ductal and endocrine differentiation, but only immuno-
histochemical staining with markers for acinar cells 
(trypsin, chymotrypsin, lipase, etc.) and endocrine 
cells (synaptophysin or chromogranin A) can identify 
the different lines of differentiation. Even though this is 
a very rare entity, two forms of mixed acinar-endocrine 
carcinoma have been observed. In one form this 
cancer has expression of acinar and endocrine markers 
in histologically distinct cell types, while in the other 
form both markers are co-expressed in the same cells 
that show both acinar and endocrine histologies[18,19]. 
However, the majority of mixed acinar-endocrine 
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carcinomas have a predominance of acinar cells[20].
MOLECULAR BIOLOGY
Understanding the role of signal transduction path-
ways responsible for cell growth and survival is 
important for development of cancer therapies. 
Secretion of pancreatic enzymes is a central role for 
acinar cells and this is evidenced by the fact they 
have the highest levels of protein synthesis of any 
adult cell[21]. Secretions from the acinar cells are 
correlated with the stage of digestion, hence pancreas 
secretion is regulated by hormones secreted by the 
digestive tract, principally cholecystokinin (CCK) and 
acetylcholine via the vagal nerve, as well as secretin. 
Increases in intracellular calcium levels play a key 
role in the control of digestive enzyme secretion, 
but extracellular stores are required too[22]. Protein 
synthesis, primarily digestive enzymes, are regulated 
by a number of pathways in the acinar cell including 
the phosphatidylinositol-4,5-bisphosphate 3-kinase 
(PI3K)/A kinase binding (AKT)/mammalian target of 
rapamycin (mTOR) pathway[23]. In terms of PACC, 
up to 25% of the PACCs were reported to have 
inactivating mutations in genes of the adenomatous 
polyposis coli (APC)-β-catenin pathway[5]. Additionally, 
these authors reported finding activating mutations in 
the CTNNB1 gene in PACC samples.
Table 1 summarizes the molecular abnormalities 
noted in PACC. Recently, one study reported finding 
DNA mismatch repair (MMR) abnormalities present 
in some acinar cell carcinomas. They examined the 
expression of DNA MMR genes by immunohisto-
chemistry (IHC) in 36 PACC cases and detected the loss 
of MMR proteins in 5 of the 36 cases (14%) examined. 
At least two of these five patients with a loss of MMR 
protein expression had a known history of Lynch 
syndrome[24]. In another case series, microsatellite 
instability (MSI) was present in 2 out of 42 specimens 
(5%) examined[25].
Comprehensive genomic profiling has been perfor-
med on a number of tumor samples taken directly 
from patients with PACCs, including those with a mixed 
acinar carcinoma phenotype and pancreatoblastomas. 
Genomic profiling using next-generation sequencing 
(NGS) - based platforms including whole exome 
sequencing was performed on these tumor samples. 
Unlike PDACs, where > 90% of cases contain various 
types of KRAS gene mutations, mutation in KRAS was 
observed only in one (a mixed acinar/neuroendocrine 
tumor) out of the total 78 PACC cases sequenced in the 
three studies[12,26,27]. In addition, genomic alterations 
in SMAD4, CDKN2A, and TP53 genes were observed 
in PACCs but less frequently than in PDACs. Other 
mutations noted in PACCs were in the BRCA1, BRCA2, 
RB1 genes, along with mutations in the WNT-β-catenin 
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Figure 1  Different histological forms of pancreatic acinar cell carcinomas. A: A case of PACC displaying nested to glandular growth patterns (HE 40 ×); B: 
Higher magnification of the same tumor in Panel A showing monotonous cells with eosinophilic/granular cytoplasm with well-defined cell borders and uniform nuclei 
with minimal atypia and prominent nucleoli (HE 200 ×); C: Tumor from a different patient showing a predominantly sheet-like growth with no distinct pattern (HE 40 ×). D: 
Higher magnification of the same tumor in C showing uniform cells with eosinophilic granular cytoplasm (prominent zymogen granules) with minimal pleomorphism (HE 
200 ×). Inset: mitotic figures were identified throughout the tumor (HE 400 ×). 
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response with first-line combination chemotherapy 
regimens[6]. Table 2 describes systemic regimens that 
have shown activity in patients with PACCs.
For patients with limited metastatic disease, resec-
tion of the sites of metastasis may result in greater 
long-term survival than patients without resection. One 
case series included six patients with metastatic PACC 
who underwent resection of metastatic disease (liver 
metastases or omental metastases); they had a two-
year overall survival rate of 67% (OS: 6-47+ mo). 
Four of these patients received adjuvant gemcitabine 
treatment in addition to resection of metastases[31].
CONCLUSION
Various genetic alterations were detected in PACCs; 
some of these mutations are potentially targetable 
by Food and Drug Administration (FDA)-approved 
medications or agents being studied for use in treating 
other malignancies. For example, BRAF inhibitors like 
vemurafenib are approved for treatment of melanoma 
with the BRAF V600E mutation[32], but these inhibitors 
have clinical activity against melanomas with the less 
common BRAF V600R mutation as well[33]. Tumors 
with DNA repair abnormalities, including BRCA gene 
mutations, show increased sensitivity to platinum 
agents. Poly ADP ribose polymerase inhibitors are 
efficacious in some BRCA mutated tumors as well[34,35]. 
One PACC patient with a loss of function mutation 
pathway (APC and CTNN1 genes). Interestingly, only 
one patient was found to have mutations in both 
the BRCA2 and CTNNB1 genes[26]. Additionally, chan-
ges were found in the BRAF/RAF1, ATM and GNAS 
genes[5,12,26,27]. Refer to Table 1 for more details.
TREATMENT
The treatment of choice for PACC is surgical resection if 
the tumor is localized and resectable. Surgical resection 
significantly improved survival; the 5-year survival 
was 72% in patients with resected PACC compared to 
16% in their counterparts with PDAC[8]. The efficacy 
of adjuvant chemotherapy and/or radiotherapy is not 
clear for patients with PACC; 50% of cases present 
with metastatic disease, most commonly to regional 
lymph nodes and the liver. In addition, 25% of patients 
develop metastatic disease after resection of the 
primary tumor[1].
PACCs are moderately responsive to chemotherapy. 
Due to the few cases that present each year, there 
are no prospective data to guide treatment decisions 
and most therapeutic regimens used are the same 
as those utilized for PDACs or colorectal carcinomas. 
Responses have been seen in PACC patients treated 
with gemcitabine- or 5-fluorouracil-based combination 
therapies with irinotecan, a platinum analog, docetaxel, 
or erlotinib[1,6,28-30]. About 50%-60% of patients with 
metastatic PACC achieve stable disease or a better 
Table 1  Somatic genetic alterations observed in pancreatic acinar cell carcinoma specimens n  (%)
Gene Ref. Number of patients Number of patients with mutation (frequency )
TP53 Jiao et al[12] 23 3 (13)
Chmielecki et al[26] 44 10 (23)
BRAF/RAF11 Jiao et al[12] 23 3 (13)
Chmielecki et al[26] 44 11 (25)
Bergmann et al[25] 42 0 (0)
SMAD4 Jiao et al[12] 23 6 (26)
Chmielecki et al[26] 44 6 (26)
BRCA2 Jiao et al[12] 23 1 (4)
Chmielecki et al[26] 44 9 (20)
Furukawa et al[27]   7 3 (43)
CDK2NA Jiao et al[12] 23 4 (17)
Chmielecki et al[26] 44 6 (14)
MMR/MSI Liu et al[24] 36 5 (14)
Bergmann et al[25] 42 2 (5)
RB1 Jiao et al[12] 23 3 (13)
Chmielecki et al[26] 44 5 (11)
APC and CTNNB1 Jiao et al[12] 23 2 (9)
Abraham et al[5] 17 4 (24)
Chmielecki et al[26] 44 4 (9)
BRCA1 Jiao et al[12] 23 0 (0%)
Chmielecki et al[26] 44 4 (9)
JAK1 Jiao et al[12] 23 4 (17)
MEN1 Jiao et al[12] 23 1 (4)
Chmielecki et al[26] 44 3 (7)
GNAS Jiao et al[12] 23 2 (9)
Chmielecki et al[26] 44 2 (5%)
FAT Furukawa et al[27]   7 4 (57)
Allelic Loss on Chromosome 11p Abraham et al[5] 12 6 (50)
1Including BRAF gene fusion and point mutations.
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in the BRCA2 gene developed liver metastasis after 
receiving gemcitabine and S-1 as first line treatment; 
subsequently, the patient achieved a complete 
remission using cisplatin and S-1 therapy and the 
patient is alive with no evidence of disease after 5 
years[27]. This was the only patient out of 11 in this 
study cohort treated with cisplatin. The results of this 
therapeutic intervention suggest that PACCs with 
BRCA2 mutations might respond well to cisplatin-
containing chemotherapy regimens. 
As mentioned earlier, 14% of PACCs tested were 
revealed to have a MMR deficiency status[24]. Mismatch 
repair status in different malignancies (including 
colorectal, endometrial, gastric, pancreas, and small 
bowel carcinomas) predicted clinical benefit for use 
of immune checkpoint blockade by treatment with 
the PD-1 receptor blocker, pembrolizumab. Patients 
with MMR-deficient tumors showed a significantly 
higher objective response rate and progression-free 
survival compared to MMR proficient patients[36]. These 
findings suggest PD-1 and PD-L1 inhibitors might 
have antitumor activity in patients with MMR-deficient 
PACCs. Pembrolizumab has been recently approved by 
the FDA for the treatment unresectable or metastatic 
mismatch repair deficient solid tumors that have pro-
gressed on prior treatment and those who have no 
satisfactory alternative treatment options.  
Comprehensive genomic analysis revealed that 23% 
of PACCs had fusions in BRAF and RAF1 genes. One in 
particular, the staphylococcal nuclease and tudor domain 
containing 1 (SND1) -BRAF fusion which results from 
an amplified, chromosomal rearrangement between 
chromosome 7q32 and 7q34. This rearrangement 
results in an overexpression of the SND1 -BRAF fusion 
protein which is constitutively active, and confers 
resistance to c-Met receptor tyrosine kinase inhibition[37]. 
Several drugs were studied in vitro for use against the 
SND1-BRAF fusion mutation, including trametenib (a 
MEK inhibitor), sorafenib (a multikinase inhibitor), and 
TAK-632 (a pan-Raf inhibitor). Trametinib was shown 
to be superior to the other agents[26]. JAK-1 somatic 
mutations were seen in some cases of PACC, so JAK 
inhibitors such as ruxolitinib (a JAK-1 and 2 inhibitors), 
which is FDA approved for myelofibrosis[38], would be 
an option to consider for PACCs containing mutations in 
JAK1/JAK2. Additionally, there are investigational drugs 
that target the Wnt pathway and could be potentially 
studied in patients with PACC tumors with APC or 
CTNNB1 gene mutations[39].
Unlike PDACs, the vast majority of PACCs are 
KRAS wild-type[12,26]. Two patients with PACC with 
liver metastases (they received two and three lines of 
prior chemotherapy, respectively) were treated with 
single agent panitumumab (an EGFR inhibitor). The 
KRAS gene was wild type in both patients. One patient 
was clinically stable for 4 mo with panitumumab 
therapy, while the other patient deteriorated clinically 
after 3 doses of the drug and then succumbed to the 
disease[40]. Panitumumab could be considered for 
refractory PACC patients with KRAS wild type tumors 
for which no other actionable targets are identified. 
In summary, with this review of the literature, 
some potentially interesting targets were identified for 
treatment of patients with PACCs. Whether targeting 
tumors with mutations in the BRAF or BRCA2 genes 
or a lack of MMR expression will be helpful to patients 
remains an issue to be settled in future clinical trials.
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